Home/Pipeline/Teriparatide

Teriparatide

Osteoporosis

Not DisclosedActive

Key Facts

Indication

Osteoporosis

Phase

Not Disclosed

Status

Active

Company

Epygen Biotech

About Epygen Biotech

Epygen Biotech is a private, US-based biopharmaceutical company founded in 2019, specializing in the development and manufacturing of biosimilar and novel therapeutic proteins. Its pipeline includes programs in oncology (Pegfilgrastim, Bevacizumab), cardiovascular (Recombinant Streptokinase), hormones (Teriparatide), and vaccines (SARS-CoV-2), supported by in-house CDMO capabilities. The company's strategy centers on leveraging its recombinant protein technology platform to produce high-quality, affordable biologics for global markets, though it appears to be in a pre-revenue or early development stage.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Immune disorders Vaccines

Other Osteoporosis Drugs

Drug	Company	Phase	Status
Biosimilar to Prolia® (denosumab)	Teva	Approved/Under Review	Launched in EU, under review in US
AGA2118	Angitia Biopharmaceuticals	Phase 2	Active
Teriparatide (PTH 1-34) Process	Numaferm	Commercial	Active
Recombinant Teriparatide	Paras Biopharmaceuticals Finland	Pre-clinical	Active
Stoboclo®/Osenvelt®	Celltrion	Marketed	Approved
SHR-1222	Jiangsu Hengrui Medicine	Phase III	Active
Biosimilar Denosumab	Richter Gedeon	Phase III	Active
Teriparatide Injection	Amphastar Pharmaceuticals	Marketed	Generic (Launched)
TST002 (Blosozumab)	Transcenta Therapeutics	Phase 1	Active